Back to search

Duquesne

Targeting the MEK5, MEK1/2, and/or PI3K Pathways to Reverse Epithelial to Mesenchymal Transition and Enhance Chemotherapeutic Sensitivity in Breast And Brain Cancers

Abstract

dc:description.abstract

Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer and accounts for 10-15% of breast cancer cases. Due to absence of estrogen, progesterone, and human epidermal growth factor receptors, there is lack of targeted therapies and chemotherapy remains the mainstay treatment. Moreover, drug resistance is a major problem associated specifically with TNBC. Similarly, while estrogen receptor positive (ER+) breast cancer can be treated with targeted therapies such as tamoxifen, 40% of patients develop resistance and resulting in recurrence of the disease. There is a dire need for identifying novel targets and developing therapeutics to target triple-negative and tamoxifen-resistant (TAMR) breast cancers. Activation of one of the newest members of mitogen-activated protein kinase (MAPK) family, extracellular-regulated kinase (ERK) 5 is known to increase cell viability, proliferation, and migration in different cancers and its overexpression correlates with poor patient survival. In breast cancer, activation of mitogen activated protein kinase kinase (MEK) 5, the upstream kinase of ERK5, and/or ERK5 promotes drug resistance, the epithelial to mesenchymal transition (EMT), and hormone independence. Once the cancer cells undergo an EMT, they are harder to target and contain, leading to metastases. Therefore, there is an urgent need to understand the pathways that drive proliferation and the EMT and develop novel therapies that target these pathways. TNBCs are heterogeneous in their mutational profile and reliance on specific signaling pathways. Therefore, in addition to the ERK5 pathway, the ERK1/2 and phosphoinositol-3-kinase (PI3K)-AKT pathways have been shown to have overlapping and distinct functions as the ERK5 pathway to regulate tumorigenesis in TNBC and TAMR breast cancers. Interestingly, inhibition of one of these signaling pathways often leads to a compensatory increased activation of the other signaling cascades. The main goals of this project are 1) to target the ERK1/2 and ERK5 pathways and develop strategies to reverse the EMT using novel and known pharmacological inhibitors and molecular tools and 2) determine the effect of novel and known kinase inhibitors on chemotherapeutic sensitivity and 3) determine the effect of novel compounds that target the ERK1/2 and ERK5 pathways in combination with the AKT inhibitor ipatasertib on spheroid viability, migration, and proliferation in TNBCs. The results from this study will aid in the design of innovative therapeutic strategies that target cancer metastases and reduce therapeutic resistance.

Degree

thesis:*
Name thesis:degree_name
PhD
Level thesis:degree_level
Immediate Access
Discipline thesis:degree_discipline
Pharmacology

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Bhatt, Akshita
Contributors dc:contributor
  • Jane E. Cavanaugh
  • Paula Witt-Enderby
  • Rehana Leak
  • Patrick T. Flaherty
  • Kevin Tidgewell

Subjects

dc:subject × 6

Rights

Language dc:language
English

Identifiers

dc:identifier.*
Repository record dc:identifier
https://dsc.duq.edu/etd/1962

Chain of custody

source
Harvested from
Duquesne
Base URL
dsc.duq.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Bhatt, Akshita. Targeting the MEK5, MEK1/2, and/or PI3K Pathways to Reverse Epithelial to Mesenchymal Transition and Enhance Chemotherapeutic Sensitivity in Breast And Brain Cancers. Immediate Access thesis, https://dsc.duq.edu/etd/1962